---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-010634"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:06:57.473884+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Omeros posts Q4 net income of $86.5M; YARTEMLEA approved, zaltenibart deal closed

## Summary
- Q4 2025 net income $86.5M ($1.22/diluted EPS) vs. net loss $31.4M ($0.54) in Q4 2024; full-year net loss narrowed to $3.4M ($0.05) from $156.8M ($2.70).
- Closed zaltenibart deal with Novo Nordisk Nov 2025, receiving $240M upfront; repaid $67.1M term loan and $17.1M convertible notes.
- FDA approved YARTEMLEA (narsoplimab) for TA-TMA Dec 2025; commercial launch began Jan 2026.
- Q4 OMIDRIA royalties $9.2M on $30.7M net sales vs. $10.1M on $33.6M in prior year.
- Operating expenses fell to $122.8M in FY25 from $167.0M in FY24, down $44.2M.

## SEC filing metadata
- accession: 0001437749-26-010634
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000143774926010634/0001437749-26-010634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000143774926010634/omer20251116_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-010634
- JSON: https://secwatch.observer/filing/0001437749-26-010634.json
- Plain text: https://secwatch.observer/filing/0001437749-26-010634.txt

## Key facts
- Earnings Releases
  OMEROS CORP reported fourth quarter and year ended December 31, 2025 results: net income Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, EPS Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million.
  - Period: fourth quarter and year ended December 31, 2025
  - Net income: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million
  - EPS: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million
  - Result: reported results
  source text: Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results – Conference Call Today at 4:30 p.m. ET
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285819/000143774926010634/0001437749-26-010634-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.